stockrow
Saturday 7 November 2026
Export QURE’s income statement to Excel — free account
uniQure N.V.
QURE Healthcare Biotechnology
uniQure N.V.’s revenue for fiscal 2025 (year ended December 2025) was $16.1 million, down 40.6% from fiscal 2024.
- Revenue
- +40.4%
- EPS
- +36.5%
- Free cash flow
- +27.7%
- Total debt
- −2.96%
Quarter to September 2026, against a year earlier
21.62
0.61
+2.90%
Follow QURE
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
83.74 | 163.41 | 56.70 | 85.48 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(35.31) | (106.77) | (26.82) | (17.74) | |
P/B ratio |
5.73 | 9.42 | 6.87 | 6.92 | |
Price to Tangible BV |
8.11 | 12.85 | 18.81 | 13.66 | |
EV/Sales |
53.50 | 123.14 | 27.50 | 50.40 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(5.61) | (14.30) | (2.89) | (4.56) | |
EV/FCF |
(5.53) | (14.05) | (2.85) | (4.49) | |
Quick Ratio |
11.19 | 9.79 | 9.97 | 9.99 | |
Current Ratio |
11.52 | 10.01 | 10.40 | 10.43 | |
Net Debt/EBITDA |
13.00 | 16.07 | 12.55 | 11.90 | |
Debt/Assets |
5.35% | 5.09% | 6.41% | 6.02% | |
Debt/Equity |
0.17 | 0.15 | 0.33 | 0.25 | |
Asset Turnover |
0.02 | 0.02 | 0.03 | 0.02 | |
Operating CF/Net income |
0.78 | 0.35 | 0.71 | 2.09 | |
Capex/Depreciation |
0.00 | (0.10) | (0.05) | (0.04) | |
Interest Coverage |
(3.63) | (3.63) | (3.26) | (3.51) | |
Research and Development Expense of Revenue |
683.55% | 581.48% | 819.09% | 624.71% | |
Selling, General and Administrative Expense of Revenue |
460.32% | 297.33% | 563.39% | 388.11% | |
Intangible Assets out of Total Assets |
0.09 | 0.09 | 0.12 | 0.12 | |
Share Based Compensation of Revenue |
104.81% | 85.88% | 142.90% | 83.75% | |
Graham Net Nets |
0.03 | 0.06 | (0.01) | 0.02 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(14.51%) | (8.71%) | (21.28%) | (14.42%) | |
Free Cash Flow Yield |
(11.56%) | (5.36%) | (17.04%) | (13.13%) | |
Revenue per Share |
0.07 | 0.09 | 0.06 | 0.10 | |
Operating CF per Share |
(0.68) | (0.43) | (0.61) | (1.35) | |
Capex per Share |
0.00 | (0.01) | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.68) | (0.44) | (0.61) | (1.35) | |
Cash per Share |
9.56 | 12.23 | 9.35 | 10.83 | |
Shareholders Equity per Share |
4.22 | 4.89 | 2.38 | 3.46 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
4.22 | 4.89 | 2.38 | 3.46 | |
Free Cash Flow |
(47.84) | (29.05) | (38.38) | (77.69) | |
Working Capital |
632.40 | 750.92 | 556.55 | 593.07 | |
Capital Expenditures |
(0.01) | (0.47) | (0.14) | (0.12) | |
Net Current Asset Value |
46.65 | 173.22 | (13.62) | 29.98 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.08 | 0.04 | 0.02 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
4.34 | 5.69 | 3.04 | 5.87 | |
Average Payables |
6.20 | 5.26 | 4.83 | 6.20 | |
Average Assets |
914.47 | 785.00 | 692.05 | 690.72 | |
Average Common Equity |
261.70 | 160.02 | 91.51 | 96.07 |
Columns are period end dates · fundamentals updated 6 Nov 2026